123 related articles for article (PubMed ID: 8809286)
1. Probable hypersensitivity reaction to filgrastim.
Martín Muñoz R; Gómez-Bellver MJ; Navarro Pulido AM; Orta Cuevas JC
Am J Health Syst Pharm; 1996 Jul; 53(13):1607. PubMed ID: 8809286
[No Abstract] [Full Text] [Related]
2. Recombinant methionyl granulocyte colony-stimulating factor (filgrastim): a new dimension in immunotherapy.
Schwab G; Hecht T
Ann Hematol; 1994 Jul; 69(1):1-9. PubMed ID: 7520285
[No Abstract] [Full Text] [Related]
3. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy.
Engert A; Griskevicius L; Zyuzgin Y; Lubenau H; del Giglio A
Leuk Lymphoma; 2009 Mar; 50(3):374-9. PubMed ID: 19347726
[TBL] [Abstract][Full Text] [Related]
4. Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.
Frampton JE; Lee CR; Faulds D
Drugs; 1994 Nov; 48(5):731-60. PubMed ID: 7530630
[TBL] [Abstract][Full Text] [Related]
5. Filgrastim for treatment of neutropenia in a neonate.
Berndt EM; Stavris MA; Hanna M; Allen P; Kulick J
Am J Health Syst Pharm; 1999 May; 56(10):995-7. PubMed ID: 10365725
[No Abstract] [Full Text] [Related]
6. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia pretreated with filgrastim mimicking acute promyelocytic leukemia.
Bartlett JR; Lunde JH
Blood; 2014 Jun; 123(25):3853. PubMed ID: 25083521
[No Abstract] [Full Text] [Related]
8. Using filgrastim efficiently.
Dranitsaris G
Pharmacoeconomics; 1996 May; 9(5):466-8. PubMed ID: 10161379
[No Abstract] [Full Text] [Related]
9. Immediate hypersensitivity to human recombinant granulocyte-macrophage colony-stimulating factor associated with a positive prick skin test reaction.
Engler RJ; Weiss RB
Ann Allergy Asthma Immunol; 1996 Jun; 76(6):531-4. PubMed ID: 8673688
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer.
Sagara Y; Sato K; Fukuma E; Higaki K; Mizutani M; Osaki A; Takano T; Tokuda Y; Ohno S; Masuda N; Suzuki M; Saeki T
Jpn J Clin Oncol; 2013 Sep; 43(9):865-73. PubMed ID: 23858037
[TBL] [Abstract][Full Text] [Related]
11. Anaphylactic reaction after a first filgrastim (granulocyte-colony stimulating factor) injection.
Batel-Copel L; Mommeja-Marin H; Oudard S; Chauvenet L; Pujade-Lauraine E; Coupier J; Bernadou A
Eur J Cancer; 1995 Dec; 31A(13-14):2428. PubMed ID: 8652291
[No Abstract] [Full Text] [Related]
12. Prophylactic granulocyte colony-stimulating factor treatment for acquired chronic severe neutropenia in pregnancy.
Sangalli MR; Peek M; McDonald A
Aust N Z J Obstet Gynaecol; 2001 Nov; 41(4):470-1. PubMed ID: 11787932
[No Abstract] [Full Text] [Related]
13. Desensitization to lenograstim after a life- threatening reaction to filgrastim.
Nuñez-Acevedo B; Rodríguez-Jiménez B; Domínguez-Ortega J; González-Montellano E; Ibáñez-Heras N; Enrech-Francés S
J Investig Allergol Clin Immunol; 2015; 25(2):158-60. PubMed ID: 25997320
[No Abstract] [Full Text] [Related]
14. Pyoderma gangrenosum complicating pegylated granulocyte colony-stimulating factor in Hodgkin lymphoma.
Miall FM; Harman K; Kennedy B; Dyer MJ
Br J Haematol; 2006 Jan; 132(1):115-6. PubMed ID: 16371028
[No Abstract] [Full Text] [Related]
15. Filgrastim--human granulocyte-colony stimulating factor.
Drug Ther Bull; 1993 Apr; 31(9):33-6. PubMed ID: 7688277
[No Abstract] [Full Text] [Related]
16. Effects of molgramostim, filgrastim and lenograstim in the treatment of myelokathexis.
Cernelc P; Andoljsek D; Mlakar U; Pretnar J; Modic M; Zupan IP; Zver S
Pflugers Arch; 2000; 440(5 Suppl):R81-2. PubMed ID: 11005621
[TBL] [Abstract][Full Text] [Related]
17. Filgrastim for lupus neutropenia.
Euler HH; Schwab UM; Schroeder JO
Lancet; 1994 Nov; 344(8935):1513-4. PubMed ID: 7526104
[No Abstract] [Full Text] [Related]
18. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy.
Gatzemeier U; Ciuleanu T; Dediu M; Ganea-Motan E; Lubenau H; Del Giglio A
J Thorac Oncol; 2009 Jun; 4(6):736-40. PubMed ID: 19404210
[TBL] [Abstract][Full Text] [Related]
19. Multiple, repeated filgrastim treatment cycles to recover severe, recurring pegylated interferon-related neutropenia.
Manfredi R; Sabbatani S
Hepatogastroenterology; 2007 Sep; 54(78):4 page preceeding table content. PubMed ID: 18019674
[No Abstract] [Full Text] [Related]
20. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
Bhana N
Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
